Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-03-29
2011-03-29
Cheu, Jacob (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C436S518000
Reexamination Certificate
active
07915002
ABSTRACT:
Disclosed is a method for controlling the therapeutic treatment of a patient suffering from cardiac insufficiency. In said method, it is determined how the concentration of at least one of the vasoactive peptides adrenomedullin (ADM), endothelin-1(ET-1), and/or vasopressin (AVP) changes in the patient's blood after beginning the therapy, and the therapeutic measures are considered to be unsatisfactory and are modified in case said concentration does not decrease at all or not enough in relation to a threshold value for the respective vasoactive peptide.
REFERENCES:
patent: 2007/0212742 (2007-09-01), Bergmann et al.
patent: 2008/0026414 (2008-01-01), Bergmann et al.
patent: 1564558 (2004-02-01), None
patent: 1619505 (2006-01-01), None
patent: 2004/090546 (2004-10-01), None
patent: 2006/018315 (2006-02-01), None
Schafer et al. (Basic Res Cardiol. 2002 vol. 97, p. 399-408).
Written Opinion of the International Search Authority for corresponding PCT/EP2007/006393.
Joachim Struck et al., “Proteolytic processing pattern of the endothelin-1 precursor in vivo”, Peptides 26 (2005) 2482-2486.
G. deGevigney et al., “Pathophysiology and therapeutic implications of left heart failure”, Science Direct (2005) (Abstract Only).
Joachim Struck et al., “Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients”, Peptides 25 (2004) 1369-1372.
Albertus Beishuizen et al., “Circulating Cardiovascular Markers and Mediators in Acute Illness: an update”, Clinica Chimica Acta 354 (2005) 21-34.
Nils G. Morgenthaler et al., “Measurement of Midregional Proadrenomedullin in Plasma with an Immunoluminometric Assay”, Clinical Chemistry 51:10, (2005), 1823-1829.
Jana Papassotiriou et al., “Immunoluminometric Assay for Measurement of the C-Terminal Endothelin-I Precursor Fragment in Human Plasma”, Clinical Chemistry 52:6, (2006), 1144-1151.
Nils G. Morgenthaler et al., “Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of Vasopressin”, Clinical Chemistry 52:1, (2006), 112-119.
Van Cheng et al., “A Rapid Bedside Test for B-Type Peptide Predicts Treatment Outcomes in Patients Admitted for Decompensated Heart Failure: A Pilot Study”, Journal of American College of Cardiology, vol. 37(2), Feb. 2001, 386-91.
Kjaer A., “Neuroendocrine activation in heart insufficiency II. Can diagnosis be confirmed and prognosis evaluated by a blood test?”, 2000.
B.R.A.H.M.S GmbH
Cheu Jacob
Heslin Rothenberg Farley & & Mesiti P.C.
LandOfFree
Method for controlling the therapy of patients suffering... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for controlling the therapy of patients suffering..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for controlling the therapy of patients suffering... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2733726